Cite
Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.
MLA
Jauw, Yvonne W. S., et al. “Assessment of Target-Mediated Uptake with Immuno-PET: Analysis of a Phase I Clinical Trial with an Anti-CD44 Antibody.” EJNMMI Research, vol. 8, no. 1, Jan. 2018, p. 1–N.PAG. EBSCOhost, https://doi.org/10.1186/s13550-018-0358-8.
APA
Jauw, Y. W. S., Huisman, M. C., Nayak, T. K., Vugts, D. J., Christen, R., Naegelen, V. M., Ruettinger, D., Heil, F., Lammertsma, A. A., Verheul, H. M. W., Hoekstra, O. S., van Dongen, G. A. M. S., & Menke-van der Houven van Oordt, C. W. (2018). Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody. EJNMMI Research, 8(1), 1–N.PAG. https://doi.org/10.1186/s13550-018-0358-8
Chicago
Jauw, Yvonne W. S., Marc C. Huisman, Tapan K. Nayak, Danielle J. Vugts, Randolph Christen, Valerie Meresse Naegelen, Dominik Ruettinger, et al. 2018. “Assessment of Target-Mediated Uptake with Immuno-PET: Analysis of a Phase I Clinical Trial with an Anti-CD44 Antibody.” EJNMMI Research 8 (1): 1–N.PAG. doi:10.1186/s13550-018-0358-8.